On March 13, 2024, Clene Inc., a clinical-stage biopharmaceutical company, announced its full-year financial results for the period ending December 31, 2023. The announcement highlighted the company's progress in its clinical programs for neurodegenerative diseases, including ALS and MS, and its discussions with the FDA regarding an accelerated approval pathway for its drug CNM-Au8. Clene reported a net loss of $49.5 million for the year, a decrease in research and development expenses, and a cash position of $35.0 million, which is expected to fund operations into Q4 2024. The company also shared significant clinical data from trials of CNM-Au8, demonstrating benefits in ALS and MS treatments. Clene met with the FDA to discuss regulatory pathways and is preparing additional data to support an accelerated approval filing. The company also highlighted the receipt of a $45.1 million NIH grant and the publication of peer-reviewed articles supporting CNM-Au8's mechanism of action.

On March 13, 2024, Clene Inc., a clinical-stage biopharmaceutical company, announced its full-year financial results for the period ending December 31, 2023. The announcement highlighted the company's progress in its clinical programs for neurodegenerative diseases, including ALS and MS, and its discussions with the FDA regarding an accelerated approval pathway for its drug CNM-Au8. Clene reported a net loss of $49.5 million for the year, a decrease in research and development expenses, and a cash position of $35.0 million, which is expected to fund operations into Q4 2024. The company also shared significant clinical data from trials of CNM-Au8, demonstrating benefits in ALS and MS treatments. Clene met with the FDA to discuss regulatory pathways and is preparing additional data to support an accelerated approval filing. The company also highlighted the receipt of a $45.1 million NIH grant and the publication of peer-reviewed articles supporting CNM-Au8's mechanism of action.